This Expert Review features internationally-renowned thought leaders discussing the latest data regarding the treatment of advanced pancreatic cancer, including safety and efficacy data on current and emerging treatment options, patient- and disease-related factors that play a role in determining optimal treatment, and the best sequence of therapy for individual patients with metastatic disease. This program also features a companion downloadable slide deck that includes details on key information covered in the discussion.
Aug 2, 2017
Aug 2, 2018
Axel Grothey, MDWest Cancer Center
Memphis, Tennessee, United States
Teresa Macarulla, MD, PhDVall d’Hebron University Hospital
Gerald Prager, MDMedical University of Vienna
- Current and emerging treatment strategies for advanced pancreatic cancer
- Patient- and disease-related factors that help determine optimal treatment selection for pancreatic cancer
- Optimal sequencing strategies for patients with metastatic pancreatic cancer
This educational activity is designed for medical oncologists, gastroenterologists, and other healthcare providers involved in the management of patients with pancreatic cancer.
After successful completion of this educational activity, participants should be able to:
- Explain factors that impact treatment decision making in metastatic pancreatic adenocarcinoma
- Evaluate available and emerging therapies for metastatic pancreatic cancer
- Identify the best sequence of therapy for individual patients with metastatic pancreatic cancer
This educational activity is supported by Shire.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.